Shares are pleased to present Ariana Resources (AAU), Avacta (AVCT) and eg solutions (EGS) at their event in London on Wednesday 26 April 2017.

The evening event provides an opportunity for board directors from these three companies to make a presentation about their company and update existing & potential investors on their business plans.

4 out of the top 10 global large pharmas and more than 10 other biotech and pharma companies are evaluating/collaborating with Avacta on their Affirmer technology which is an engineered alternative to antibodies. The company CEO, Alastair Smith, will provide an update on its recent news release about the Affirmer immunogenicity study using human samples.

Avacta's focus is on its proprietary Affimer platform technology, a novel engineered alternative to antibodies, that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth more than $75bn despite their shortcomings. Affimer technology, based on a small, robust protein, can be quickly generated to bind with high specificity and affinity to a wide range of targets, addressing many of the limitations of antibodies.

Avacta has a pre-clinical Affimer drug development programme with a focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors.

Ariana Resources (AAU) - Ariana have just started to produce and pour gold on their Red Rabbit venture in Turkey. Managing Director Kerim Sener will be updating investors at the Shares event on progress to date and what else is in store for the company in 2017.

Avacta (AVCT) - 4 out of the top 10 global large pharmas and more than 10 other biotech and pharma companies are evaluating/collaborating with Avacta on their Affirmer technology which is an engineered alternative to antibodies.

eg solutions (EGS) - the rapidly growing creators of enterprise workforce optimisation software and a services company has seen its share price grow by 50% this year on the back of some substantial licensing deals. Elizabeth Gooch will give an update on these deals and others in the pipeline.

Presenters:

Kerim Sener, MD - Ariana Resources (AAU)

Alastair Smith, CEO - Avacta (AVCT)

Elizabeth Gooch, MBE, CEO - eg solutions (EGS)

Shareholders and potential investors can register now for free at: http://www.sharesmagazine.co.uk/events


At 12:01pm: (LON:AVCT) Avacta Group PLC share price was 0p at 69.5p